DeMol
Design, analyze, and fund real drugs on chain
Demo
About
The problem it solves Traditional drug discovery is slow, expensive, and centralized—often requiring years of lab work and millions in funding before a molecule even reaches preclinical validation. Promising discoveries made by independent researchers frequently go unfunded or unnoticed due to lack of access to institutional support. DeMol solves this by: - Enabling AI-powered molecule generation and evaluation in minutes rather than months. - Providing a platform for scientists and researchers to submit, score, and showcase promising compounds without needing a big pharma pipeline. - Tokenizing high-quality molecules as on-chain IP, making them tradable, fundable, and verifiable from day one. - Letting a decentralized community (DAO) vote on which molecules deserve funding—creating a global, democratized R&D engine. - Streamlining the IP lifecycle, from generation to validation and funding, using automation, verifiable AI, and smart contracts. What people can use it for: - Researchers can validate and monetize their discoveries. - DAOs and investors can fund molecules and earn royalties from future licensing. - Developers can contribute AI agents, tools, or data pipelines.
How it's made
Challenges we ran into - **ELiZA Inference Mapping:** Customizing agent actions to be recognized and executed correctly within ELiZA’s framework. - **Lightweight Deployment:** Running ELiZA agents on small servers (e.g., AWS micro instances) caused performance bottlenecks. - **Toxicity Model Balance:** Managing performance across multiple toxicity endpoints with limited data.